PT2977 (Belzutifan, MK-6482), an orally active and selective HIF-2α inhibitor, increases potency and improves pharmacokinetic profile, providing a potential treatment for clear cell renal cell carcinoma (ccRCC).
此产品仅用于科学研究,我们不为任何个人用途提供产品和服务
PT2977 (Belzutifan, MK-6482), an orally active and selective HIF-2α inhibitor, increases potency and improves pharmacokinetic profile, providing a potential treatment for clear cell renal cell carcinoma (ccRCC).
[1] Xu R, et al. J Med Chem. 2019 Aug 8;62(15):6876-6893.
没有评价数据